Administering Dysport®

Identifying authentic Dysport®

The best way to protect your patients from counterfeit Dysport is to verify that you’re ordering authentic Dysport from an authorized distributor. Be sure to check the packaging of your product to make sure it’s authentic.

There are more anti-counterfeiting measures on the packaging that aren’t listed here. Ask your distributor for more information.


Dosing for moderate to severe glabellar lines

Dilution chart for the treatment of moderate to severe glabellar lines1
Dilution for 300-U vial Concentration
1.5 mL 10 U/0.05 mL
2.5 mL 10 U/0.08 mL
  • Dysport is supplied as a single-use, sterile, 300-U vial, reconstituted with sterile, preservative-free, 0.9% sodium chloride solution. Do not use Dysport after the expiration date on the vial.1
  • Dysport contains a unique hologram on the carton. If you do not see the hologram, do not use the product. Instead, contact 855-463-5127.

Download the Dysport Reconstitution Guide

Important information about the Dysport® injection process.

Before injecting and treating patients with Dysport, take note of the location, size, and use of muscles.1

  • Have patient frown while you palpate the tensed muscle mass. Physicians administering Dysport must understand the relevant neuromuscular and/or orbital anatomy of the area involved and any alterations to the anatomy due to prior surgical procedures.
  • Identify the lateral corrugator and vertical procerus muscles. The corrugator depresses the skin, creating a "furrowed" vertical line surrounded by tensed muscle.
  • Inject Dysport by advancing a 30-gauge needle through the skin into the underlying muscle while applying finger pressure on the superior medial orbital rim.
  • Inject a total of 50 U of Dysport in 5 equally divided aliquots of 10 U into each of 5 sites, 2 in each corrugator muscle, and 1 in the procerus muscle.

Note: Location, size, and use of muscles vary markedly among individuals.

Important safety information about ptosis*

  • Carefully examine the upper lid for separation or weakness of the levator palpebrae muscle (true ptosis), evaluate lash ptosis, and identify range of lid excursion while manually depressing the frontalis to assess compensation.
  • Avoid injecting near the levator palpebrae superioris, particularly in patients with larger brow depressor complexes.
  • Inject into the medial corrugator at least 1 cm above the bony supraorbital ridge.
  • Ensure the injected volume/dose is accurate and, where feasible, kept to a minimum.
  • Do not inject Dysport closer than 1 cm above the central eyebrow.
  • To avoid increased risk of ptosis, adhere to recommended dosage.

*An abnormally low position or drooping of the upper eyelid

DOSAGE AND ADMINISTRATION: The potency Units of Dysport are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of Dysport cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.

See below for Dysport Important Safety Information and Full Prescribing Information, including Boxed Warning.

  1. Dysport Prescribing Information. Fort Worth, TX: Galderma Laboratories, L.P. December 2016.


Indication: Dysport® (abobotulinumtoxinA) for Injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients ˂65 years of age.

Distant Spread of Toxin Effect

Postmarketing reports indicate that the effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including upper limb spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.


Warnings and Precautions

Adverse Reaction

Drug Interactions

Use in Specific Populations

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

Please see Dysport Full Prescribing Information, including Medication Guide.